# Synthesis of Tricyclic and Tetracyclic Lactone Derivatives of Thieno[2,3-b]pyrazine or Thieno[2,3-b]quinoline: Preliminary Antitumor and Antiparasitic Activity Evaluation

**Authors:** Maria F. Martins, Francisco Ribeiro, Ana Borges, Ricardo C. Calhelha, Nuno Santarém, Anabela Cordeiro-da-Silva, Maria-João R. P. Queiroz

PMC · DOI: 10.3390/molecules30091999 · Molecules · 2025-04-30

## TL;DR

This paper describes the synthesis of new tricyclic and tetracyclic lactone compounds and tests their potential as antitumor and antiparasitic agents.

## Contribution

The study introduces novel synthetic methods for tricyclic and tetracyclic lactones and evaluates their preliminary biological activity.

## Key findings

- A Sonogashira product showed strong antitumor activity with GI50 < 10 µM across five cancer cell lines.
- Some compounds exhibited antiparasitic activity against Trypanosoma brucei and Leishmania infantum with IC50 < 11 µM.
- Tetracyclic lactones were synthesized via Rh(III)-catalyzed [4+2] cycloaddition with good yields.

## Abstract

Tricyclic and tetracyclic lactone derivatives of thieno[2,3-b]pyrazine or thieno[2,3-b]quinoline, and 2H-pyrones were prepared using different methodologies. Pd/Cu-catalyzed Sonogashira coupling using Et3N as a base, of methyl 7-bromothieno[2,3-b]pyrazine-6-carboxylate and (het)arylalkynes to yield the Sonogashira ester products, gave also the corresponding tricyclic lactones as minor products. However, the major products did not cyclize with TFA. Tricyclic lactones were then obtained by a tandem one-pot Sonogashira coupling and 6-endo-dig lactonization of 7-bromothieno[2,3-b]pyrazine-6-carboxylic acid with (het)arylalkynes, in good yields. Halogenated tricyclic lactones were synthesized by halocyclization using CuX and NXS. Tetracyclic lactones were synthesized through a Rh(III)-catalyzed formal [4+2] cycloaddition, between thieno[2,3-b]quinoline-2-carboxylic acid and internal alkynes, triggered by C-H activation, with the carboxylic group acting as a directing group. Using the SRB assay, the antitumor activity of both Sonogashira products and lactones was evaluated across five human cancer cell lines (CaCo-2, MCF-7, AGS, HeLa, NCI-H460). The best-performing compound was a Sonogashira product showing a GI50 < 10 µM in all tumor cell lines and low toxicity in PLP2 cells. Additionally, antiparasitic testing against Trypanosoma brucei and Leishmania infantum revealed some compounds with IC50 < 11 µM, though some level of cytotoxicity was observed in THP-1—derived macrophages.

## Linked entities

- **Chemicals:** Et3N (PubChem CID 8471), TFA (PubChem CID 6422), CuX (PubChem CID 138403229), NXS (PubChem CID 2776521)
- **Diseases:** cancer (MONDO:0004992)
- **Species:** Trypanosoma brucei (taxon 5691), Leishmania infantum (taxon 5671)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), cytotoxicity (MESH:D064420)
- **Species:** Homo sapiens (human, species) [taxon 9606], Trypanosoma brucei (species) [taxon 5691], Leishmania infantum (species) [taxon 5671]
- **Cell lines:** CaCo-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), AGS — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0139), NCI-H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), PLP2 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_TE71)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12073635/full.md

## Figures

43 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12073635/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12073635/full.md

---
Source: https://tomesphere.com/paper/PMC12073635